On November 18, 2021 GT Medical Technologies, Inc. a company dedicated to improving the lives of patients with brain tumors, reported upcoming presentations related to its breakthrough GammaTile Therapy at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO) being held in Boston November 18-21, 2021 (Press release, GT Biopharma, NOV 18, 2021, View Source [SID1234595825]). In total, GammaTile will be showcased in seven clinical presentations as well as an Industry-Sponsored Symposium.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing updated data, clinical experiences of GammaTile users, and ongoing trials evaluating GammaTile Therapy with our neuro-oncology colleagues at the SNO conference this week," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "These presentations add to the mounting clinical evidence supporting the use of GammaTile Therapy in patients with brain tumors."

A list of educational presentations and their respective authors are below. The full text of these presentations is available in the November supplement of Neuro-Oncology, the official journal of the Society for Neuro-Oncology.

Poster Session: Friday, November 19th, 7:30 PM – 9:30 PM, Exhibit Hall D
A Multicenter Observational Study Of Cs-131 Seeds Embedded In A Collagen Carrier Tile For Newly Diagnosed And Recurrent Operable Intracranial Neoplasms –Trial In Progress, Erin Dunbar, MD
Successful Safety And Efficacy Of GammaTile Intracranial Brachytherapy Implanted During Awake Craniotomy, Ulysses G. Gardner, Jr., MD, MBA
Phase III Multicenter RCT Of Post-Surgical Stereotactic Radiotherapy Versus Surgically Targeted Radiation Therapy For The Treatment Of Large Newly Diagnosed Brain Metastases – Trial In Progress, Jeffrey S. Weinberg, MD
Access To Specialty Radiation Care For Patients With Resectable Brain Tumors, Mehee Choi, MD
Lunch Independent Symposium Session: Saturday, November 20th, 12:45 PM – 1:45 PM
GammaTile Therapy: Surgically Targeted Radiation Therapy For Brain Tumors, David Brachman, MD, Clark C. Chen, MD, PhD, Erin Dunbar, MD, Brandon Imber, MD
Abstract Session: Sunday, November 21st, 10:10 AM – 10:15 AM, Room 208
First Experience With Maximal Safe Resection And GammaTile Brachytherapy As Treatment For Recurrent Glioblastoma, Clark C. Chen, MD, PhD
Concurrent Session: Sunday, November 21st, 11:50 AM – 12:10 PM, Ballroom C
Revisiting Brachytherapy In The Treatment Of Recurrent Glioblastoma, Peter Nakaji, MD
Published Abstract Available Online
Resection And Surgically Targeted Radiation Therapy For Treatment Of Locally Recurrent GBM In 28 Prospectively Treated Patients, Kris Smith, MD

On November 18, 2021 Lunit, a leading medical AI provider, reported that the US Food and Drug Administration (FDA) 510(k) has cleared its AI solution for breast cancer detection, ‘Lunit INSIGHT MMG’ (Press release, Lunit, NOV 18, 2021, View Source [SID1234595824]). Along with its chest x-ray triaging solution ‘Lunit INSIGHT CXR Triage’, the company’s AI solution for both chest x-ray and mammography is now commercially available across the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am delighted to deliver the great news and to introduce Lunit INSIGHT MMG to healthcare professionals and institutions across the US," said Brandon Suh, CEO of Lunit. "With our AI solution, we hope to increase the efficiency and accuracy of mammography screening as well as chest x-ray triaging. We can assist radiologists diagnose diseases at an earlier stage, helping patients be treated at the right time."

Lunit INSIGHT MMG is one of the company’s most mature radiology products which analyzes mammography images with high accuracy. It provides the location of lesions suspicious of breast cancer and an abnormality score that reflects the AI’s confidence of the existence of detected lesions.

The product is trained with a large-scale data of more than 240,000 mammography cases that include up to 50,000 breast cancer cases, and is known to show excellent performance in finding breast cancer at an earlier stage.

According to a study published in JAMA Oncology in 2020, Lunit INSIGHT MMG showed the best accuracy among three commercialized AI to identify breast cancer. It was found to have around 15% higher sensitivity compared to the other two algorithms. The FDA-cleared AI solution has been previously CE marked and approved for commercial sales in more than 35 countries worldwide.

"This is a huge milestone and business opportunity for us, as the US is one of the largest and most important markets that covers more than 45% of the global breast imaging market," added Suh. "Based on the FDA clearance, we will not only bring diagnostic value to medical professionals and patients in the US, but leverage our business to be a leading global provider of breast AI solution."

Lunit INSIGHT MMG will be showcased at RSNA 2021, scheduled to be held on 28 Nov – 2 Dec 2021, in Chicago. Lunit booth will be located in AI Showcase, booth #4545.

On November 18, 2021 Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, reported that data on BTM-3566, in development for the treatment of hematological malignancies including Diffuse Large B-cell Lymphoma, was selected for an oral presentation at the 63rd Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), being held from December 11- 14, 2021, virtually and in-person in Atlanta (Press release, Bantam Pharmaceutical, NOV 18, 2021, View Source [SID1234595823]). Dr. Adrian Schwarzer, MD, PhD, Hannover Medical School, will present non-clinical research on the activity and mechanism of BTM-3566 a novel, oral compound that targets mitochondrial dynamics leading to cellular stress and tumor cell apoptosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the abstract and oral presentation session are as follows:

Title

BTM-3566, a Novel Activator of the Mitochondrial Stress Response Promotes Robust Therapeutic Responses in Vitro and In Vivo in Diffuse Large B-Cell Lymphoma

Date

Monday, December 13, 2021, 4:00 P.M. ET

Location

Georgia World Congress Center, Room B213-B214, Level 2

Presenter

Adrian Schwarzer, MD, PhD, Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Abstract

Available online at: View Source

Accepted abstracts are currently available in a special online-only issue of Blood, ASH (Free ASH Whitepaper)’s official journal, at View Source

About BTM-3566

BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique and differentiated from other therapeutics, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is being completed for submission in Q1 2022.

On November 18, 2021 Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that data from a Phase 1 study investigating its MultiTAA-specific T cells were selected for oral presentation at the 2021 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Marker Therapeutics, NOV 18, 2021, View Source [SID1234595821]). The results will be reviewed by investigators at the Baylor College of Medicine, Marker’s research partner. ASH (Free ASH Whitepaper) will take place from December 11-14, 2021, in Atlanta and in a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details

Presentation Title: Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL (Abstract #471)
Session Title: 704. Cellular Immunotherapies: Cellular Therapies for ALL
Session Date/Time: Sunday, December 12, 2021, 12:30 p.m. ET
Presenting Author: Dr. Swati Naik, MBBS, Center for Cell and Gene Therapy, Baylor College of Medicine
Location: Georgia World Congress Center, B401-B402 and virtual

The abstract is available on the American Society of Hematology (ASH) (Free ASH Whitepaper) 2021 Annual Meeting website and in a supplement to the November issue of Blood, an ASH (Free ASH Whitepaper) journal.

On November 18, 2021 Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, reported that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on Tuesday, November 30, at 2:40 p. m. E.T (Press release, Dynavax Technologies, NOV 18, 2021, https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-4th-annual-evercore-virtual-isi-healthconx-conference-301428589.html [SID1234595819]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source A replay of the webcast will be available for 30 days following the live event.